Latest News From Lumira Ventures

Antios Therapeutics Initiates First-in-Human Phase 1 Study of ATI-2173

Jennifer Schram Antios Therapeutics, Portfolio News, Press Release

ATLANTA /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases, today announced it has initiated its first-in-human Phase 1 clinical trial for ATI-2173, a novel liver-targeted, orally-administered, …

Zymeworks Announces Closing of US$320.8M Public Offering

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics (“Zymeworks” or the “Company”), announced today the closing of its previously announced underwritten public offering (the “Offering”). The Offering consisted of 5,824,729common shares, including the …

Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia—(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME) (“Zymeworks” or the “Company”), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, has today filed a preliminary prospectus supplement (the “Canadian Supplement”) to its Canadian short form base shelf prospectus dated November 18, …

Zymeworks Inks Collaboration Agreement with Pfizer in Breast Cancer Study

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific …

enGene Expands Senior Management Team

Jennifer Schram enGene, Portfolio News, Press Release

BOSTON and MONTRÉAL /PRNewswire/ – enGene Inc., the biotechnology company developing rationally designed gene therapies targeted to mucosal tissues through its proprietary non-viral vector DDX® platform, today announced the appointments of Sharon Tan as Vice President and Head of Program Management, and Lance …